Science & Enterprise subscription

Follow us on Twitter

  • Start-up companies working in artificial intelligence scored sizeable increases in venture financing, and were high… https://t.co/oLdLmHGz1M
    about 18 hours ago
  • New post on Science and Enterprise: Venture Funds, Mergers in A.I. Up Sharply in 2018 https://t.co/rimak87tjS #Science #Business
    about 18 hours ago
  • Wish it weren't needed, but ... https://t.co/SZAb2GO2vz
    about 3 days ago
  • The Edelman public relations agency released results of a survey earlier this month gauging the public's awareness… https://t.co/XaxxGJOYQl
    about 3 days ago
  • New post on Science and Enterprise: Infographic – Public, Tech Execs Differ on A.I. Use https://t.co/cvVj3IyCR0 #Science #Business
    about 3 days ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Gene Editing Deactivates Cause of T-Cell Side Effects

Human T-cell

A biotechnology company developing engineered T-cells as treatments for cancer, used gene editing to deactivate a likely cause of serious adverse effects from its therapies. . . . → Read More: Gene Editing Deactivates Cause of T-Cell Side Effects

Gene Therapy Company Acquired in $4.3B Deal

Retinal gene therapy

Spark Therapeutics, a biotechnology company that pioneered gene therapies, is being acquired by drug maker Roche Group in a deal valued at $4.3 billion. . . . → Read More: Gene Therapy Company Acquired in $4.3B Deal

Start-Up Raises $10.5M for Precision Immunotherapies

Business newspaper

A new biotechnology enterprise developing personalized treatments that harness the immune system to treat cancer is raising $10.5 million in its first venture funding round. . . . → Read More: Start-Up Raises $10.5M for Precision Immunotherapies

Targeted Chemo Seen Benefiting Breast Cancer Patients

Breast cancer self exam

A clinical trial shows a treatment combining an antibody and chemotherapy drug invokes a response and longer survival time in many patients with metastatic triple-negative breast cancer. . . . → Read More: Targeted Chemo Seen Benefiting Breast Cancer Patients

Trial Shows RNA Therapy Safe for Diabetes

Blood glucose test

Results from a clinical trial show a new drug with synthetic messenger RNA is safe for people with diabetes, and has the potential to promote new blood vessel growth. . . . → Read More: Trial Shows RNA Therapy Safe for Diabetes

High-Speed Screens, A.I., Boost Nanoscale Medicines

Spherical nucleic acid illustration

Biomedical engineers are using high-throughput screening techniques and machine learning to speed and improve the design of new drugs based on nanoscale particles. . . . → Read More: High-Speed Screens, A.I., Boost Nanoscale Medicines

Stem Cell Genes Edited to Avoid Immune Rejection

Sonja Schrepfer and Tobias Deuse

A new study shows editing the genomes of adult stem cells can avoid their rejection by the immune system when implanted in lab mice other than the stem cell donor. . . . → Read More: Stem Cell Genes Edited to Avoid Immune Rejection

Genetic Engineering, Silencing Boost Plant Output

Growing test plants

An agricultural research lab uses genetic engineering and gene silencing to produce crop plants that increase their yields by more than 40 percent. . . . → Read More: Genetic Engineering, Silencing Boost Plant Output

FDA Approves 25 Precision Meds in 2018

Onpattro

An organization advocating for medicines addressing a person’s unique chemical composition rather than disease symptoms says U.S. regulators approved 25 of those drugs in 2018. . . . → Read More: FDA Approves 25 Precision Meds in 2018

UC-Berkeley to Get New Crispr Patent

U.S. Patent and Trademark Office

University of California in Berkeley will soon receive a new patent for its development of the genome editing process known as Crispr, the latest round in a years-long dispute. . . . → Read More: UC-Berkeley to Get New Crispr Patent